Lataa...
Approaches for relapsed CLL after chemotherapy-free frontline regimens
Novel agents, including Bruton’s tyrosine kinase inhibitors (BTKi; ibrutinib, acalabrutinib), venetoclax, and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib, duvelisib), have fundamentally changed the chronic lymphocytic leukemia (CLL) treatment landscape, allowing for a chemotherapy-fr...
Tallennettuna:
| Julkaisussa: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727527/ https://ncbi.nlm.nih.gov/pubmed/33275712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000168 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|